Addex (ADXN) CEO Timothy Dyer Exercises Options

What Happened

• Timothy M. Dyer, CEO of Addex Therapeutics Ltd. (ADXN), exercised options and had option strike prices repriced on Sept 2, 2026. The Form 4 reports issuance/acquisition of 16,413,787 common shares and adjustments to 3,369,796 derivative units. The filing shows $0.00 per share reported, but footnotes state the post‑repricing exercise price is $0.032 per share (USD, converted from CHF).
• Based on the $0.032 strike in the filing footnotes, the implied cash cost would be about $525,241 for the 16,413,787 shares and about $107,834 for the 3,369,796 derivative units — roughly $633,075 total (approximate). The filing notes these transactions are exempt under Rule 16b‑6(d) and Rule 16b‑3.

Key Details

• Transaction date: September 2, 2026; Form 4 filed: September 4, 2026 (appears timely — within the two business day requirement).
• Reported price on Form 4: $0.00; footnotes state repriced exercise price = $0.032 per share (USD), conversion rate CHF→USD = 1.2296.
• Shares issued/acquired: 16,413,787 common shares; derivative adjustments: 3,369,796 units.
• Footnotes: F1 explains these 16.41M shares were acquired following prior option exercises (originally issued under deferred strike payment plans on 10/26/2022 and 11/27/2023); F2/F3 confirm repricing to $0.032 and the USD conversion.
• Shares owned after the transaction: not specified in the excerpt of the filing provided.

Context

• These are option exercises/repricing actions (not open‑market buys or sales). Repricing lowers the strike implied cash needed to exercise and does not by itself signal a sale; the filing shows no immediate open‑market sale of the newly issued shares.
• The transactions were reported as exempt under Sections cited (Rule 16b‑6(d) and Rule 16b‑3), which relates to certain company plan transactions and officer compensation mechanics and limits short‑swing recovery applicability.
• For retail investors: exercises and repricings change insider economic exposure but are administrative/compensation actions — they are factual events to note, not direct endorsements or sales of the stock.